Alternative Splicing of the First Intracellular Loop of Plasma Membrane Ca2+-ATPase Isoform 2 Alters Its Membrane Targeting*

Michael C. ChickaDagger and Emanuel E. Strehler§

From the Department of Biochemistry and Molecular Biology, Mayo Graduate School, Mayo Clinic, Rochester, Minnesota 55905

Received for publication, February 11, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Plasma membrane Ca2+-ATPases (PMCAs) are involved in local Ca2+ signaling and in the spatial control of Ca2+ extrusion, but how different PMCA isoforms are targeted to specific membrane domains is unknown. In polarized MDCK epithelial cells, a green fluorescent protein-tagged PMCA4b construct was targeted to the basolateral membrane, whereas a green fluorescent protein-tagged PMCA2b construct was localized to both the apical and basolateral domain. The PDZ protein-binding COOH-terminal tail of PMCA2b was not responsible for its apical membrane localization, as a chimeric pump made of an NH2-terminal portion from PMCA4 and a COOH-terminal tail from PMCA2b was targeted to the basolateral domain. Deletion of the last six residues of the COOH terminus of either PMCA2b or PMCA4b did not alter their membrane targeting, suggesting that PDZ protein interactions are not essential for proper membrane localization of the pumps. Instead, we found that alternative splicing affecting the first cytosolic loop determined apical membrane targeting of PMCA2. Only the "w" form, which contains a 45-amino acid residue insertion, showed prominent apical membrane localization. By contrast, the x and z splice variants containing insertions of 14 and 0 residues, respectively, localized to the basolateral membrane. The w splice insert was the crucial determinant of apical PMCA2 localization, and this was independent of the splice configuration at the COOH-terminal end of the pump; both PMCA2w/b and PMCA2w/a showed prominent apical targeting, whereas PMCA2x/b, PMCA2z/b, and PMCA2z/a were confined to the basolateral membrane. These data report the first differential effect of alternative splicing within the first cytosolic loop of PMCA2 and help explain the selective enrichment of specific PMCA2 isoforms in specialized membrane compartments such as stereocilia of auditory hair cells.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Plasma membrane Ca2+-ATPases (PMCAs)1 constitute the major high affinity Ca2+ extrusion system of eukaryotic cells. Their function is crucial for the maintenance of the normally low cytosolic free Ca2+ levels ([Ca2+]i) in resting cells and to counteract the transient increases in [Ca2+]i generated during Ca2+ signaling (1, 2). The spatially and temporally distinct demands on Ca2+ influx and efflux mandate the proper spatial distribution and abundance of the PMCAs across the plasma membrane. This is of particular importance in polarized cells such as neurons or epithelial cells where Ca2+ signaling often must be restricted to the pre- and post-synaptic membrane (neurons) or where Ca2+ influx and efflux must be spatially segregated between the apical and basolateral membrane (Ca2+ transporting epithelia). However, the molecular determinants and the mechanisms by which PMCAs are targeted to distinct membrane domains are unknown.

Mammalian PMCAs are encoded by four separate genes giving rise to PMCA isoforms 1-4. Isoform complexity is further enhanced by alternative splicing of the primary transcripts, such that over 20 distinct PMCA variants exist in the mammalian proteome (2). Alternative splicing affects two major regions of the protein (splice sites A and C): the first intracellular loop between membrane-spanning domains 2 and 3, and the COOH-terminal tail which corresponds to a major regulatory region of the pump and contains its calmodulin-binding site (Fig. 1).


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 1.   Scheme of PMCA2 and its major splice variants. A model of the PMCA is shown on top, with its membrane-spanning domains indicated by gray boxes and the lipid bilayer as two horizontal bars. The NH2- (N) and COOH terminus (C) is indicated, as is the first cytosolic loop with a phospholipid-sensitive region (PL), the large intracellular catalytic loop, and the two major splice sites A and C. The alternatively spliced exons are shown as separate boxes, and their sizes in nucleotides (nt) are indicated in a scheme of the genomic organization on the bottom. The exon configuration and nomenclature of the major human PMCA2 splice variants are also shown.

Alternative splicing at site A does not change the overall reading frame of the pump; instead, varying numbers of amino acids (from 14 to 45 in human PMCA2) are optionally inserted into the intracellular loop separating membrane-spanning segments 2 and 3 (Fig. 1). Splicing at site A is most complex in PMCA2 where the optional insertion of three separate exons leads to splice variant 2w (all three exons included), 2x (only the third exon included), 2y (only the first two exons included), and 2z (none of the alternative exons included) (2). The functional effect of alternative splicing at site A is unknown, although it has been noted that the changes occur close to a phospholipid-binding domain of the pump (3, 4). The first intracellular loop also participates in the pump mechanism as the so-called A (actuator) domain (5).

The main splice variants (termed "a" and "b") generated at the COOH-terminal site differ in their primary amino acid sequence due to a change in reading frame. Functionally, the most notable consequence of COOH-terminal splicing is a difference in calmodulin regulation of the respective pump variants (2, 6). In addition, the extreme COOH-terminal sequence of the b splice variants (but not of the a-forms) has been shown recently to interact with several PDZ proteins including members of the synapse-associated protein family (7), NO synthase I (8), and Na+/H+ exchanger regulatory factor-2 (NHERF2) (9). Differential interaction with specific PDZ proteins may be one mechanism for the membrane targeting or retention of specific transporters or receptors. We recently reported (7) that PMCA4b is almost exclusively localized in the basolateral membrane of polarized Madin-Darby canine kidney (MDCK) epithelial cells where it may interact with the PDZ protein synapse-associated protein 97. By contrast, we found that a GFP-tagged PMCA2b isoform was mainly targeted to the apical membrane where it co-localized with NHERF2 as a specific interaction partner (9).

Here we first set out to test the hypothesis that alternative splicing affecting the COOH-terminal tail may lead to differential membrane targeting of PMCAs. By using recombinant protein expression and confocal fluorescence microscopy, we find that the PDZ binding tail is dispensable for basolateral or apical membrane targeting, suggesting that COOH-terminal splicing plays no primary role for the proper localization of PMCA isoforms. Surprisingly, however, alternative splicing at site A influences apical or basolateral localization of PMCA2. PMCA2w, but not -2x or -2z, is targeted to the apical membrane, and this is true regardless of whether the COOH-terminal splice corresponds to the a or b variant. Our data suggest for the first time a role for alternative splicing at site A of PMCA2, indicating the importance of this splicing event for differential membrane targeting of the calcium pump in polarized cells.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Construction of PMCA Expression Vectors-- GFP-PMCA4b encoding human PMCA4x/b fused at its NH2 terminus to GFP was generated by cloning an XhoI fragment carrying the full-length PMCA4x/b sequence into pEGFP-C2 (Clontech). The PMCA4x/b sequence was PCR-amplified using pMM2-PMCA4b (3) as template together with primers 4b-start (5'-ggg ggc tcg aga acg aac cca tca gac cgt gtc ttg cc-3') and 4b-stop (5'-ccc cct cga gtc aaa ctg atg tct cta ggc tct gta g-3') containing XhoI recognition sequences (underlined). The full-length coding sequence of PMCA2x/b was first assembled as a NotI fragment in pBluescript-KS using reverse transcriptase-PCR and cDNAs cloned previously (4). To generate full-length cDNAs for PMCA2w/b and PMCA2z/b, a BstEII-SphI fragment encompassing the alternative splice site A region in PMCA2x was replaced by corresponding cassettes containing the 2w and 2z sequence, respectively. The NotI fragments carrying the full-length PMCA2w/b, -2x/b, or -2z/b coding sequence were then excised from pBluescript-KS and subcloned into the NotI site of pSPORT-1 (Invitrogen). Finally, the PMCA2 sequences were cloned as MluI-SalI (2w/b and 2x/b) or MluI-KpnI fragments (2z/b) into the modified pMM2 expression vector (3) to generate pMM2-PMCA2w/b, pMM2-PMCA2x/b, and pMM2-PMCA2z/b. To create constructs for GFP-PMCA2w/b and GFP-PMCA2x/b, the full-length PMCA2w/b and PMCA2x/b sequences were released as SacII/XbaI fragments from the original pBluescript-KS vectors and cloned into a modified pEGFP-C1 expression vector (Clontech) containing consecutive hemagglutinin and His6 tags (10) between the GFP and the respective PMCA sequences. To make constructs GFP-PMCA2w/bDelta 6 and GFP-PMCA2x/bDelta 6, a GFP-PMCA2b plasmid described previously (9) was used as starting material because it allowed access to a convenient downstream restriction site. First, an ~250-bp EcoRI-SalI fragment encoding the COOH-terminal 72 residues was replaced by a corresponding PCR-generated EcoRI-SalI fragment carrying a translational stop codon six residues upstream of the original terminus. An ~2.3-kb BglII fragment containing the NH2-terminal ~750 codons was then excised from this plasmid and replaced by corresponding BglII fragments from GFP-PMCA2w/b and GFP-PMC2x/b to create the constructs GFP-PMCA2w/bDelta 6 and GFP-PMCA2x/bDelta 6, respectively. The expression vector pMM2-PMCA2z/a has been described previously (11). The expression vector pMM2-PMCA2w/a was generated by a three-way ligation combining SalI-KpnI-digested pMM2 plasmid DNA, an ~1.3-kb SalI-ScaI fragment from GFP-PMCA2w/b (containing the 5' end coding sequence including the "w" insert at splice site A), and an ~2.4-kb ScaI-KpnI fragment from pMM2-PMCA2z/a (containing the 3' region and a-tail sequence at splice site C). The chimeric PMCA construct GFP-PMCA4x/2btail was made by replacing an ~350-bp BamHI fragment specifying the COOH-terminal residues from 1100 to 1205 in GFP-PMCA4b with a BamHI fragment specifying the corresponding COOH-terminal sequence from plasmid GFP-PMCA2b (9). The final construct encodes a GFP-tagged chimeric PMCA consisting of residues 1-1100 of PMCA4 (x splice variant) fused to the COOH-terminal 112 residues of PMCA2 (b splice variant). The integrity of all constructs was confirmed by DNA sequencing in the Mayo Molecular Biology Core Facility. A schematic representation of all constructs is shown in Fig. 2.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 2.   Scheme of PMCA constructs. The recombinant PMCAs used in this study are shown schematically and are labeled on the left. The green fluorescent protein moiety is represented by a black box; PMCA2 is gray, and PMCA4 is white. Splice sites A and C are indicated by arrows. Sequences encoded by alternatively spliced exon are shown as differently stippled boxes. Deletion of the six COOH-terminal residues is indicated by a small black box.

Expression of Recombinant PMCAs and Immunoblotting-- COS-1 cells were grown to ~80% confluence on 6-well plates (Costar) in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, non-essential amino acids, 1 mM sodium pyruvate, glutamine, and antibiotic/antimycotic mixture (all cell culture reagents from Invitrogen). Cells were transfected with 2 µg of plasmid DNA using LipofectAMINE PlusTM according to the manufacturer's instructions (Invitrogen). After ~48 h, the cells were rinsed, lysed as described (7), and the protein concentration in the lysates determined by the BCA assay (Pierce). About 30 µg of the lysates from untransfected (control) and transfected cells were separated on 7.5% SDS-polyacrylamide gels and transferred to nitrocellulose following standard Western blotting procedures (12). Nitrocellulose membranes were blocked in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1% Tween + 5% milk before detection of the PMCAs using specific antibodies. Monoclonal Pan-PMCA antibody 5F10, monoclonal anti-PMCA4 antibody JA9, and affinity-purified polyclonal anti-PMCA2 antibody NR-2 were obtained from John Penniston and Adelaida Filoteo (Mayo Clinic) and used at dilutions of 1:2000, 1:600, and 1:5000, respectively. Secondary goat anti-mouse or goat anti-rabbit antibodies coupled to horseradish peroxidase were purchased from Sigma and used at 1:5000 dilution. Incubation with primary and secondary antibodies, washing, and detection of the signals was done as described previously (13).

Confocal Fluorescence Microscopy-- Type I MDCK epithelial cells (ATCC number CCL-34, Manassas, VA) were grown to confluence on glass coverslips in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. Cells were transfected with a total of 2 µg of plasmid DNA using LipofectAMINE 2000TM (Invitrogen). 48 h after transfection, the cells were fixed for 15 min at room temperature in 4% paraformaldehyde (Tousimis, Rockville, MD) diluted in DPBS + Ca2+/Mg2+ (DPBS + CM, Invitrogen). After five brief washes in DPBS + CM, coverslips were further fixed and permeabilized in pre-chilled methanol for 15 min at -20 °C. The cells were blocked in DPBS + CM containing 5% normal goat serum and 1% bovine serum albumin (blocking buffer) and were then incubated for 1 h at room temperature with affinity-purified polyclonal anti-PMCA2 antibody NR-2 (1:1000, final concentration 0.8 µg/ml) or monoclonal Pan-anti-PMCA antibody 5F10 (1:800). After washing 3 times for 5 min in DPBS + CM, the cells were incubated for 1 h at room temperature with the appropriate anti-rabbit or anti-mouse secondary antibodies coupled to Alexa 488 or Alexa 594 (Molecular Probes, Eugene, OR). The secondary antibodies were used at a dilution of 1:800, and all antibodies for immunofluorescence were diluted in blocking buffer. 4',6'-Diamidino-2-phenylindole dihydrochloride (DAPI, Molecular Probes, Eugene, OR) was also added to the secondary antibody application at a dilution of 1:500 (final concentration 20 µg/ml) to stain nuclei. After final washing, coverslips were mounted in Prolong mounting media (Molecular Probes). Confocal micrographs were taken on a Zeiss LSM510 microscope using an Apochromat 63× oil immersion objective and captured using LSM510 software version 2.8 (Zeiss). Images were imported and edited using Adobe Photoshop 5.0.

Quantification of Apical Membrane Fluorescence-- MDCK cells were grown to confluence as a monolayer on glass coverslips, transfected with PMCA2 expression constructs and prepared for immunofluorescence as described above using anti-PMCA2 antibody NR-2 and Pan-PMCA antibody 5F10 followed by Alexa 488 and Alexa 594 secondary antibodies, respectively. Confocal images were captured on a Zeiss LSM510 microscope as mentioned above. Images of the apical most 2-µm section of 20 representative cells from each transfection were collected, applying the same detector gain, zoom, amplitude offset and gain, transmission percent, pinhole size, and scan speed for each image collected within the frame mode and using an average from two images. By using the circular-shaped fixed area tool, an arbitrary area was selected that encompassed a majority of the collected apical images of each cell without incorporating any of the area outside of the apical domain (such as the lateral "rim" of the cell). This fixed circle-shaped area was then placed on the apical domain of the apical images in order to collect the mean fluorescence intensity (using the green channel) per given surface area for each of the 20 images from each of the different transfections. Choosing a circle that encompasses most of the membrane is essential as it yields an unbiased sampling of the entire apical domain as a whole and negates any effects (such as sampling microdomains with exceptionally high or low abundance of apical protein expression) that would skew the overall mean intensity for a given image. Each cell could then be represented by a number equal to the mean apical fluorescence intensity of that cell. These numbers were used to construct a line graph showing the mean intensity for each of the 20 cells from a given transfection and were also displayed in a bar graph showing the averages of the 20 mean fluorescence intensities for each of the PMCA2 transfections.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Differential Targeting of PMCA Isoforms in Polarized MDCK Cells-- We noted previously that endogenous PMCA4b was almost exclusively expressed in the basolateral membrane of polarized MDCK cells (7, 14), whereas a significant amount of GFP-tagged PMCA2b was found at the apical membrane where it co-localized with its binding partner NHERF2 (9). To confirm that the observed difference in membrane targeting is not due to the NH2-terminally added GFP moiety, we expressed GFP-PMCA4b in MDCK cells and compared its localization to that of GFP-PMCA2b. Both GFP-tagged proteins were readily expressed in transiently transfected COS cells as determined by Western analysis using isoform-specific antibodies (Fig. 3). When expressed in polarized Madin-Darby canine kidney cells, GFP-PMCA4b was still targeted to the basolateral membrane (Fig. 4A), whereas the GFP-PMCA2b construct was prominently present at the apical membrane in addition to labeling the basolateral membrane (Fig. 4B). Thus, the difference in membrane localization of these two PMCA isoforms is not due to the presence of the GFP moiety at their NH2 terminus.


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 3.   Expression of recombinant PMCA constructs. Western blots are shown of protein lysates from COS cells transfected with various GFP-tagged (top panel) or untagged (bottom panel) PMCA constructs as indicated on top of each lane and as illustrated in Fig. 2. Equal amounts of cell lysates (~30 µg) were separated on 7.5% denaturing polyacrylamide gels, and the proteins were transferred to nitrocellulose membranes. The membranes were probed with antibodies against PMCA2 to detect GFP-tagged PMCA2w/b, -2w/bDelta 6, and -2x/bDelta 6 as well as untagged PMCA2w/a and -2z/a, with antibodies against PMCA4 to detect GFP-tagged PMCA4x/b, or with a Pan-PMCA antibody to detect the GFP-PMCA4x/2btail chimera, the non-tagged PMCA2w/b, -2x/b, and -2z/b as well as the endogenous COS-cell PMCAs (untransfected control). The position of an ~130-kDa marker protein is indicated on the left. All constructs expressed a recombinant protein of the expected size, and all constructs were expressed at comparable levels.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 4.   Different membrane localization of PMCA isoforms. GFP-tagged PMCA4b (A) and PMCA2b (B) constructs were transiently expressed in MDCK cells, and their localization was determined by confocal fluorescence microscopy. A, GFP-PMCA4x/b is localized to the (baso-) lateral membrane (right panel, en face view of section at middle height) with virtually no staining of the apical membrane (left panel, apical section). The basolateral localization of the GFP-PMCA4b isoform is obvious from the x:z section shown below the en face views. B, GFP-PMCA2w/b shows prominent apical localization (left panel, apical section) in addition to lateral staining (right panel, middle section). The apical and lateral localization of this GFP-PMCA2b isoform is easily seen in the x:z section on the bottom. The white arrows indicate where the apical and middle sections were taken for the en face views. Nuclei were stained with DAPI (blue fluorescence). Scale bar, 30 µm in en face images in A, 15 µm in en face views in B, and 10 µm in x:z sections in A and B.

Differential Membrane Targeting of PMCA2b and PMCA4b Is Not Due to Their COOH-terminal Tails-- Different PMCA b splice variants interact promiscuously with several PDZ proteins but also recognize specific PDZ protein partners (7, 9). For example, PMCA2b, but not PMCA4b, binds to NHERF2 which is a member of a small subfamily of PDZ proteins involved in membrane trafficking, anchoring, and regulation of ion transporters and receptors including Na+/H+ exchanger-3 (15), beta 2-adrenergic receptor (16), and the cystic fibrosis transmembrane conductance regulator (17, 18). The differential localization of PMCA2b and PMCA4b might therefore be dependent upon different protein-protein interactions by their COOH-terminal tails. To test this hypothesis, we generated a chimeric construct (GFP-PMCA4x/2btail, see Fig. 2) in which the GFP-PMCA4b COOH-terminal tail downstream of residue 1100 was replaced by the corresponding tail of PMCA2b. When expressed in polarized MDCK cells, the localization of this chimera was indistinguishable from GFP-PMCA4b, i.e. the chimeric pump was exclusively found in the basolateral membrane (Fig. 5). Thus, the presence of the PMCA2b COOH-tail does not impart apical targeting on a chimeric protein with its NH2-terminal segment derived from PMCA4.


View larger version (109K):
[in this window]
[in a new window]
 
Fig. 5.   Basolateral localization of a PMCA4-PMCA2b chimera. MDCK cells were transfected with the GFP-PMCA4x/2b-tail construct encoding a GFP-tagged chimeric PMCA consisting of a PMCA4 NH2-terminal portion fused to the COOH-terminal portion from PMCA2b. After fixing, the cells were incubated with Pan-PMCA antibody 5F10 and an Alexa 594-labeled secondary antibody to visualize all PMCAs (including endogenous PMCA in the non-transfected cells). Nuclei were stained by DAPI. The corresponding x:z section is shown below the en face view. The arrow indicates the level at which the en face section was taken. Note the prominent localization of the chimeric PMCA in the basolateral membrane. Bar = 10 µm.

Alternative Splicing at Site A Determines Differential Membrane Localization of PMCA2b Variants-- Although PMCA2 and PMCA4 differ at many sequence positions throughout their length (their overall identity amounts to about 75%), the most obvious divergence between these isoforms occurs at splice site A. Indeed, we noted that our basolaterally targeted GFP-PMCA4b construct corresponded to the 4x/b variant, whereas the apically targeted GFP-PMCA2b construct corresponded to the 2w/b form (see Fig. 1 for a scheme of the splice variants). To test if the splice site A configuration might be involved directly in the different membrane targeting, we constructed expression vectors for each of the known human splice site A variants of PMCA2b, i.e. hPMCA2w/b, -2x/b, and -2z/b (Fig. 2). To rule out any possible effect of the NH2-terminal GFP moiety, these vectors were made without any tag to represent the wild-type full-length PMCA2 variants. Western blots of equal amounts of total cell lysate from transfected COS cells showed that all constructs were expressed at comparable levels (Fig. 3). When expressed in polarized MDCK cells, PMCA2x/b and PMCA2z/b were primarily localized in the basolateral membrane (Fig. 6, middle and right panels), whereas PMCA2w/b showed prominent apical localization in addition to basolateral staining (Fig. 6, left panel). This difference in membrane localization was readily seen by taking confocal "en face" sections at different depths of the cells and is best illustrated in the x:z images shown in Fig. 6. Because all three constructs correspond to the b splice variant at their COOH-terminal end and are identical except for the insertion of 45 (w-form), 14 (x-form), or 0 (z-form) amino acid residues in their first intracellular loop, the observed differences in membrane localization must be due to the changes that occurred at splice site A, specifically to the insertion of 31 extra residues in the w splice form.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 6.   Differential membrane localization of splice site A variants of PMCA2b. Full-length PMCA2w/b, PMCA2x/b, and PMCA2z/b were expressed in polarized MDCK cells, and their localization was studied by confocal fluorescence microscopy. Recombinant PMCA2 was detected with isoform-specific polyclonal antibody NR-2 followed by anti-rabbit Alexa 488 (green fluorescence). Nuclei were stained with DAPI and appear blue. PMCA2w/b shows prominent apical localization in addition to basolateral staining (left panel), whereas PMCA2x/b and PMCA2z/b are exclusively localized to the basolateral membrane (middle and right panel). Corresponding x:z sections are shown below the en face views. White arrows indicate the height at which the en face sections were captured. Bar, 20 µm in en face views and 10 µm in x:z sections.

The PDZ Protein-binding COOH-terminal Sequence Is Not Required for Differential Membrane Targeting of PMCA2 Splice Site A Variants-- The experiment using a chimeric GFP-PMCA4x/2b-tail construct (see Fig. 5) had already shown that the COOH-terminal tail is not the major determinant for apical versus basolateral targeting of the PMCAs. However, the presence of a functional PDZ-binding sequence may still be required for faithful membrane targeting of the pumps. To test if this is the case, we expressed GFP-PMCA2w/b and GFP-PMCA2x/b constructs lacking their six COOH-terminal residues (Figs. 2 and 3), thus rendering them unable to interact with PDZ proteins. As shown in Fig. 7, GFP-PMCA2w/bDelta 6 and GFP-PMCA2x/bDelta 6 were still faithfully targeted to the apical and basolateral membranes, respectively, as predicted from their splice site A configuration. Similarly, GFP-PMCA4x/bDelta 6 was targeted only to the basolateral membrane (not shown), as had been observed for the corresponding full-length PMCA4x/b isoform (Fig. 4A). We conclude that a functional PDZ-binding domain at the COOH terminus is not required for targeting of the PMCAs and hence that PDZ protein interactions are dispensable for directing the pumps to their membrane destination.


View larger version (48K):
[in this window]
[in a new window]
 
Fig. 7.   The PDZ binding COOH-terminal sequence is not required for differential localization of PMCA2b splice site A variants. GFP-tagged PMCA2w/bDelta 6 and PMCA2x/bDelta 6 were expressed in MDCK cells, and their localization was determined by confocal fluorescence microscopy. Nuclei were stained with DAPI. Note the prominent apical targeting of PMCA2w/bDelta 6 (left panel) compared with the mostly basolateral localization of PMCA2x/bDelta 6 (right panel). Corresponding x:z sections are shown below each en face view. Arrows indicate the height at which the en face images were captured.

The w Insertion at Splice Site A Determines Apical Membrane Targeting of PMCA2 Isoforms-- If the insertion of the 31 extra amino acids of the w splice variant were indeed a major determinant of apical targeting of PMCA2, we would expect all w variants to be targeted to the apical membrane irrespective of the splice configuration at their COOH termini. To test this hypothesis, we generated expression vectors for full-length PMCA2w/a and PMCA2z/a (Figs. 2 and 3). When these constructs were transfected into MDCK cells, PMCA2z/a localized to the basolateral membrane, whereas PMCA2w/a showed prominent apical localization (Fig. 8). Thus, the targeting of PMCA2w/a and PMCA2z/a is identical to that of PMCA2w/b and PMCA2z/b, respectively. To obtain a more quantitative assessment of the apical/basolateral targeting of the different splice site A variants, we determined the apical membrane fluorescence intensity in multiple randomly selected cells transfected with either PMCA2w/b, 2x/b, 2z/b, 2w/a, or 2z/a as described under "Experimental Procedures." A plot of the relative fluorescence intensity in a fixed area of the apical membrane is shown in Fig. 9A for 20 individual cells from each transfection experiment, and the averaged apical fluorescence intensity for each PMCA2 construct is displayed in Fig. 9B. The data illustrate the negligible localization of PMCA2x/b, -2z/b, and -2z/a in the apical membrane, in contrast to the abundant presence of PMCA2w/b and -2w/a in this membrane compartment. The results also show that PMCA2w/b and PMCA2w/a are about equally abundant in the apical membrane, further supporting the primary importance of the w splice configuration in determining PMCA2 membrane distribution.


View larger version (44K):
[in this window]
[in a new window]
 
Fig. 8.   The splice site A configuration determines the membrane localization of PMCA2 irrespective of the splice site C configuration. Full-length PMCA2w/a and PMCA2z/a were expressed in MDCK cells, and their localization was studied by confocal fluorescence microscopy. Detection of recombinant PMCAs was as described in the legend to Fig. 6. DAPI-stained nuclei appear blue. Note that the w splice form of PMCA2a shows prominent localization in the apical membrane (left panel), whereas the z splice form is confined to the basolateral membrane (right panel) as was found for the localization of PMCA2w/b and PMCA2z/b, respectively (see Fig. 6). Corresponding x:z sections are shown below each en face view. Arrows indicate the height at which the en face images were captured.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 9.   Quantitative evaluation of apical membrane fluorescence of PMCA2 splice site A variants expressed in polarized MDCK cells. MDCK cells were transfected with PMCA2w/b, -2x/b, -2z/b,- 2w/a, or -2z/a and stained with PMCA2-specific antibody NR-2 followed by anti-rabbit Alexa 488 secondary antibody. Cells were imaged under the confocal fluorescence microscope, and images were captured of apical membrane sections of multiple randomly selected transfected cells. The fluorescence intensity per area was determined as described under "Experimental Procedures," and the data for 20 individual cells from each transfection are plotted in arbitrary units in A. The average apical fluorescence intensity for each PMCA2 construct was calculated from the data in A and is graphically displayed in B. Note the significant apical fluorescence for PMCA2w/b and PMCA2w/a compared with the almost negligible apical fluorescence for PMCA2x/b, -2z/b, and -2z/a. The data in B represent average fluorescence intensities ± S.E.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Dynamic and spatially segregated changes in Ca2+ form the basis for the exquisite specificity of intracellular Ca2+ signaling. This is achieved through subcellular compartmentalization and expression of an appropriate "tool kit" of Ca2+ transporting, buffering, and signaling molecules (19, 20). Although the PMCAs are thought to be primarily responsible for the global maintenance of the low resting [Ca2+]i, recent data suggest that they participate in local Ca2+ handling and help shape the duration and spreading of subplasmalemmal Ca2+ signals (8, 21-24). Accordingly, many PMCA isoforms and splice variants are differentially expressed and localized in several tissues and cell types. For example, auditory and vestibular hair cells of the inner ear almost exclusively express PMCA2a in their apical stereocilia. In the basolateral membrane, these same cells express mainly PMCA1b (25). Similarly, in the retina of the mouse, PMCA1 is highly abundant in the synaptic terminal and inner segment of photoreceptors but absent from the outer segment, and PMCA2 is concentrated in the synaptic membrane of rod bipolar cells in the inner plexiform layer (26).

Differential localization in distinct membrane domains may be one of the distinguishing features among PMCA isoforms and splice variants. Because the most pronounced difference between PMCA splice variants occurs between the a and b COOH-terminal splice variants, it was tempting to speculate that their different tails carry the information for differential membrane targeting. Moreover, only the b variants are known to interact with PDZ domains (7, 27), and PDZ protein interactions have been shown to be involved in the targeting, retention, and/or anchoring of several membrane receptors and ion channels (28, 29). Contrary to findings with the cystic fibrosis transmembrane conductance regulator and other transporters (30-32), our results show that the targeting of PMCAs in polarized MDCK cells is independent of their splice site C configuration and does not require a functional PDZ-interacting COOH-terminal tail. Instead, we have uncovered an important role for changes at splice site A in directing PMCA2 variants to the apical versus basolateral membrane. Only the variant with the largest insert of 45 residues (PMCA2w) was apically directed, whereas PMCA2x (14-residue insert) and PMCA2z (no extra amino acids inserted) were localized in the basolateral membrane.

The importance of the splice site A configuration for apical/basolateral targeting of PMCA2 is supported by recent isoform detection and cellular localization studies. The apical stereociliary membrane of auditory and vestibular hair cells is highly enriched for the PMCA2w/a variant (25). In lactating mammary glands, PMCA2 is also expressed at very high levels in the apical membrane of epithelial cells where it is believed to play an essential role in transcellular Ca2+ transport into the (milk) lumen. In this tissue, the splice form corresponds to PMCA2w/b (33, 34). Thus, in both cases where PMCA2 shows apical localization in polarized cell types, its splice configuration corresponds to the w variant at site A. By contrast, the splice site C configuration appears to be of lesser importance as it is a in one cell type but b in the other. Interestingly, Dumont et al. (25) recently identified a novel PMCA2 splice site A variant expressed in the apical stereocilia of frog cochlear hair cells. This variant, termed "v," encodes an even longer insert of 57 amino acids, consisting of the 45 residues found in the w variant and an additional 12 residues encoded by a separate exon. In mammals, however, a PMCA2 splice site A variant corresponding to frog PMCA2v has never been observed.

Our knowledge concerning the spatial organization of Ca2+ extrusion mechanisms at the plasma membrane is limited. Although the molecular characterization of the two major transport systems, the PMCAs and the Na+/Ca2+ exchangers, has advanced rapidly over the last few years (reviewed in Refs. 2, 35, and 36), the mechanisms by which these proteins are targeted to specific membrane domains and assembled into functional units with other Ca2+ signaling molecules remain to be elucidated. How could the w insert at splice site A alter the membrane targeting of PMCA2? Two different but not mutually exclusive possibilities are as follows: 1) a change in the interaction of the pump with specific lipids, and 2) a difference in protein-protein interactions. Interestingly, the splice site A insert is situated immediately NH2-terminal to a phospholipid-sensitive region in the first cytosolic loop of the pump (37) (see Fig. 1). The 31 extra amino acids of the w splice form may alter the structural properties of the adjacent phospholipid-sensitive region and/or membrane-spanning domains to enable their preferential interaction with lipids enriched in apical membranes. The w insert is rich in hydrophobic (Ala and Leu) as well as in helix-breaking (Gly and Pro) residues (3, 4) and may thus assume a unique structural conformation. This structural motif may be involved in specific protein-protein interactions, e.g. with proteins involved in apical targeting or apical protein retention. A differential yeast two-hybrid screen with the first cytosolic loop of the w and x (or z) splice variants as bait may provide an attractive future approach to this problem.

Finally, alternative splicing at site A of PMCA2 appears to be highly regulated. In IMR32 neuroblastoma cells, a specific and rapid switch from the 2w to the 2x variant occurs upon KCl depolarization. This splice switch is dependent on a rise in intracellular Ca2+, is independent of new protein synthesis, and can be observed within 30-45 min of cell stimulation (38). Although differential membrane distribution of PMCA2x and 2w variants has not been investigated in IMR32 cells, it is of interest that depolarization and a rise in Ca2+ are triggers of (neuronal) differentiation. Perhaps the alternative splice switch at site A of PMCA2 allows the cell to quickly re-distribute PMCA2 to membrane domains where they are needed. In neurons, this could be at newly forming synaptic sites in the dendrites. In epithelial cells of the mammary gland or the distal kidney, the PMCA2w splice form may be targeted to apical membranes in response to hormonal regulation of transcellular Ca2+ flux. Thus, alternative RNA splicing affecting the first cytosolic loop of PMCA2 appears to be a means for the regulated re-deployment of this Ca2+ pump to different membrane domains.

    ACKNOWLEDGEMENTS

We are grateful to Billie-Jo Brown and Anne Vrabel for help with the construction of the PMCA2b expression plasmids and to Aida Filoteo and Dr. John Penniston (Mayo Clinic, Rochester, MN) for antibodies against the PMCAs. We thank Dr. Steve DeMarco for experimental advice and for teaching one of us (M. C.) how to operate the confocal microscope.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant GM-58710 and by the Mayo Foundation for Medical Education and Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Present address: Program in Cellular and Molecular Biology, University of Wisconsin, Madison, WI 53706.

§ To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, Mayo Clinic/Foundation, 200 First St. S.W., Rochester, MN 55905. Tel.: 507-284-9372; Fax: 507-284-2384; E-mail: strehler.emanuel@mayo.edu.

Published, JBC Papers in Press, March 6, 2003, DOI 10.1074/jbc.M301482200

    ABBREVIATIONS

The abbreviations used are: PMCAs, plasma membrane Ca2+-ATPases; MDCK, Madin-Darby canine kidney; GFP, green fluorescent protein; DAPI, 4',6'-diamidino-2-phenylindole; NHERF2, Na+/H+ exchanger regulatory factor-2; DPBS, Dulbecco's phosphate-buffered saline; CM, Ca2+/Mg2+.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Carafoli, E. (1991) Physiol. Rev. 71, 129-153[Free Full Text]
2. Strehler, E. E., and Zacharias, D. A. (2001) Physiol. Rev. 81, 21-50[Abstract/Free Full Text]
3. Adamo, H. P., and Penniston, J. T. (1992) Biochem. J. 283, 355-359[Medline] [Order article via Infotrieve]
4. Heim, R., Hug, M., Iwata, T., Strehler, E. E., and Carafoli, E. (1992) Eur. J. Biochem. 205, 333-340[Abstract]
5. Toyoshima, C., Nakasako, M., Nomura, H., and Ogawa, H. (2000) Nature 405, 647-655[CrossRef][Medline] [Order article via Infotrieve]
6. Penniston, J. T., and Enyedi, A. (1998) J. Membr. Biol. 165, 101-109[CrossRef][Medline] [Order article via Infotrieve]
7. DeMarco, S. J., and Strehler, E. E. (2001) J. Biol. Chem. 276, 21594-21600[Abstract/Free Full Text]
8. Schuh, K., Uldrijan, S., Telkamp, M., Röthlein, N., and Neyses, L. (2001) J. Cell Biol. 155, 201-205[Abstract/Free Full Text]
9. DeMarco, S. J., Chicka, M. C., and Strehler, E. E. (2002) J. Biol. Chem. 277, 10506-10511[Abstract/Free Full Text]
10. Rogers, M. S., and Strehler, E. E. (2001) J. Biol. Chem. 276, 12182-12189[Abstract/Free Full Text]
11. Elwess, N. L., Filoteo, A. G., Enyedi, A., and Penniston, J. T. (1997) J. Biol. Chem. 272, 17981-17986[Abstract/Free Full Text]
12. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (eds) (1998) Current Protocols in Molecular Biology , pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., New York
13. Usachev, Y. M., Toutenhoofd, S. L., Goellner, G. M., Strehler, E. E., and Thayer, S. A. (2001) J. Neurochem. 76, 1756-1765[CrossRef][Medline] [Order article via Infotrieve]
14. Kip, S. N., and Strehler, E. E. (2003) Am. J. Physiol. 284, F122-F132
15. Weinman, E. J., Steplock, D., Wang, Y., and Shenolikar, S. (1995) J. Clin. Invest. 95, 2143-2149[Medline] [Order article via Infotrieve]
16. Hall, R. A., Premont, R. T., Chow, C. W., Blitzer, J. T., Pitcher, J. A., Claing, A., Stoffel, R. H., Barak, L. S., Shenolikar, S., Weinman, E. J., Grinstein, S., and Lefkowitz, R. J. (1998) Nature 392, 626-630[CrossRef][Medline] [Order article via Infotrieve]
17. Short, D. B., Trotter, K. W., Reczek, D., Kreda, S. M., Bretscher, A., Boucher, R. C., Stutts, M. J., and Milgram, S. L. (1998) J. Biol. Chem. 273, 19797-19801[Abstract/Free Full Text]
18. Wang, S., Raab, R. W., Schatz, P. J., Guggino, W. B., and Li, M. (1998) FEBS Lett. 427, 103-108[CrossRef][Medline] [Order article via Infotrieve]
19. Berridge, M. J., Lipp, P., and Bootman, M. D. (2000) Nat. Rev. Mol. Cell Biol. 1, 11-21[CrossRef][Medline] [Order article via Infotrieve]
20. Bootman, M. D., Lipp, P., and Berridge, M. J. (2001) J. Cell Sci. 114, 2213-2222[Medline] [Order article via Infotrieve]
21. Usachev, Y. M., DeMarco, S. J., Campbell, C., Strehler, E. E., and Thayer, S. A. (2002) Neuron 33, 113-122[Medline] [Order article via Infotrieve]
22. Zhong, N., Beaumont, V., and Zucker, R. S. (2001) J. Neurosci. 21, 9598-9607[Abstract/Free Full Text]
23. Bruce, J. I. E., Yule, D. I., and Shuttleworth, T. J. (2002) J. Biol. Chem. 277, 48172-48181[Abstract/Free Full Text]
24. Caride, A. J., Penheiter, A. R., Filoteo, A. G., Bajzer, Z., Enyedi, Á., and Penniston, J. T. (2001) J. Biol. Chem. 276, 39797-39804[Abstract/Free Full Text]
25. Dumont, R. A., Lins, U., Filoteo, A. G., Penniston, J. T., Kachar, B., and Gillespie, P. G. (2001) J. Neurosci. 21, 5066-5078[Abstract/Free Full Text]
26. Krizaj, D., DeMarco, S. J., Johnson, J., Strehler, E. E., and Copenhagen, D. R. (2002) J. Comp. Neurol. 451, 1-21[CrossRef][Medline] [Order article via Infotrieve]
27. Kim, E., DeMarco, S. J., Marfatia, S. M., Chishti, A. H., Sheng, M., and Strehler, E. E. (1998) J. Biol. Chem. 273, 1591-1595[Abstract/Free Full Text]
28. Fanning, A. S., and Anderson, J. M. (1999) Curr. Opin. Cell Biol. 11, 432-439[CrossRef][Medline] [Order article via Infotrieve]
29. Hung, A. Y., and Sheng, M. (2002) J. Biol. Chem. 277, 5699-5702[Free Full Text]
30. Moyer, B. D., Denton, J., Karlson, K. H., Reynolds, D., Wang, S., Mickle, J. E., Milewski, M., Cutting, G. R., Guggino, W. B., Li, M., and Stanton, B. A. (1999) J. Clin. Invest. 104, 1353-1361[Abstract/Free Full Text]
31. Rongo, C., Whitfield, C. W., Rodal, A., Kim, S. K., and Kaplan, J. M. (1998) Cell 94, 751-759[Medline] [Order article via Infotrieve]
32. Kaech, S. M., Whitfield, C. W., and Kim, S. K. (1998) Cell 94, 761-771[Medline] [Order article via Infotrieve]
33. Reinhardt, T. A., and Horst, R. L. (1999) Am. J. Physiol. 276, C796-C802[Medline] [Order article via Infotrieve]
34. Reinhardt, T. A., Filoteo, A. G., Penniston, J. T., and Horst, R. L. (2000) Am. J. Physiol. 279, C1595-C1602
35. Carafoli, E. (1994) FASEB J. 8, 993-1002[Abstract/Free Full Text]
36. Blaustein, M. P., and Lederer, W. J. (1999) Physiol. Rev. 79, 763-854[Abstract/Free Full Text]
37. Brodin, P., Falchetto, R., Vorherr, T., and Carafoli, E. (1992) Eur. J. Biochem. 204, 939-946[Abstract]
38. Zacharias, D. A., and Strehler, E. E. (1996) Curr. Biol. 6, 1642-1652[Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.